Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sandrine Le Guellec is active.

Publication


Featured researches published by Sandrine Le Guellec.


Pharmaceutical Research | 2008

Aerodynamical, Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization

Agnès Maillet; Nicolas Congy-Jolivet; Sandrine Le Guellec; Laurent Vecellio; Sophie Hamard; Yves Courty; Anthony Courtois; Francis Gauthier; P. Diot; Gilles Thibault; Etienne Lemarié; Nathalie Heuzé-Vourc’h

PurposeDespite an increasing interest in the use of inhalation for local delivery of molecules for respiratory diseases and systemic disorders, methods to deliver therapy through airways has received little attention for lung cancer treatment. However, inhalation of anticancer drugs is an attractive alternative route to systemic administration which results in limited concentration of the medication in the lungs, and triggers whole-body toxicity. In this study, we investigated the feasibility of nebulization for therapeutic antibodies, a new class of fully-approved anticancer drugs in oncology medicine.Materials and methodsCetuximab, a chimeric IgG1 targeting the epidermal growth factor receptor (EGFR), was nebulized using three types of delivery devices: a jet nebulizer PARI LC+®, a mesh nebulizer AeronebPro® and an ultrasonic nebulizer SYST’AM® LS290. Aerosol size distribution was measured using a cascade impactor and aerosol droplets were observed under optical microscopy. The immunological and pharmacological properties of cetuximab were evaluated following nebulization using A431 cells.ResultsThe aerosol particle clouds generated with the three nebulizers displayed similar aerodynamical characteristics, but the IgG formed aggregates in liquid phase following nebulization with both the jet and ultrasonic devices. Flow cytometry analyses and assays of EGFR-phosphorylation and cell growth inhibitions on A431 demonstrated that both the mesh and the jet nebulizers preserved the binding affinity to EGFR and the inhibitory activities of cetuximab.ConclusionsAltogether, our results indicate that cetuximab resists the physical constraints of nebulization. Thus, airway delivery represents a promising alternative to systemic administration for local delivery of therapeutic antibodies in lung cancer treatment.


International Journal of Pharmaceutics | 2011

Deposition of aerosols delivered by nasal route with jet and mesh nebulizers

Laurent Vecellio; Ruth De Gersem; Sandrine Le Guellec; Gregory Reychler; Laurent Pitance; Déborah Le Pennec; P. Diot; Gilles Chantrel; Pierre Bonfils; François Jamar

PURPOSE To quantify the amount of aerosol deposited in different parts of the airways with a commercially available nasal sonic jet nebulizer (NJN) using a sound effect, and to compare its performance with a new nasal mesh nebulizer (NMN). METHODS Seven healthy non-smoking male volunteers aged 21-36 years with a mean weight of 77±10 kg were included in this single-center study. Both nebulizer systems were loaded with (99m)Tc-DTPA and scintigraphies were performed with a gamma camera. Particle size distribution of the aerosols produced by the two nebulizer systems was measured. RESULTS There was no statistical difference between the two nebulizers in terms of fraction of particles smaller than 5 μm (44±4% vs 45±2%) (p>0.9). Aerosol deposition in the nasal region was 73±10% (% of aerosol deposited in airways) with the NJN, and 99±3% with the NMN (p=0.01). Total nasal deposition was 9.6±1.9% of the nebulizer charge with the NJN and 28.4±8.9% with the NMN (p=0.01). 0.5±0.3% of the nebulizer charge was deposited in the maxillary sinuses with the NJN, compared to 2.2±1.6% with the NMN (p=0.01). CONCLUSION Although the two nebulizers had the same particle size, NMN significantly improved aerosol deposition in nasal cavity and prevents deposition into the lungs.


European Annals of Otorhinolaryngology, Head and Neck Diseases | 2012

Sonic aerosol therapy to target maxillary sinuses

Marc Durand; Sandrine Le Guellec; Jérémie Pourchez; Francis Dubois; Gérald Aubert; Gilles Chantrel; Laurent Vecellio; Cloé Hupin; Ruth De Gersem; Gregory Reychler; Laurent Pitance; P. Diot; François Jamar

AIM Intranasal aerosol administration of drugs is widely used by ENT specialists. Although clinical evidence is still lacking, intranasal nebulization appears to be an interesting therapeutic option for local drug delivery, targeting anatomic sites beyond the nasal valve. The sonic nebulizer NL11SN associates a 100Hertz (Hz) sound to the aerosolization to improve deposition in the nasal/paranasal sinuses. The aim of the present study was: to evaluate in vivo the influence of associating a 100Hz sound on sinus ventilation and nasal and pulmonary aerosol deposition in normal volunteers, and; to quantify in vitro aerosol deposition in the maxillary sinuses in a plastinated head model. MATERIAL AND METHODS Scintigraphic analysis of (81m)Kr gas ventilation and of sonic aerosol ((99m)Tc-DTPA) deposition using the NL11SN was performed in vivo in seven healthy volunteers. In parallel, NL11SN gentamicin nebulization was performed, with or without associated 100Hz sound, in a plastinated human head model; the gross amount of gentamicin delivered to the paranasal sinuses was determined by fluorescence polarization immunoassay. RESULTS Associating the 100Hz sound to (81m)Kr gas ensured paranasal sinus ventilation in healthy volunteers. (99m)Tc-DTPA particles nebulized with the NL11SN were deposited predominantly in the nasal cavities (2/3, vs 1/3 in the lungs). In vitro, the use of NL11SN in sonic mode increased gentamicin deposition threefold in the plastinated model sinuses (P<0.002); the resulting antibiotic deposit would be sufficient to induce a local therapeutic effect. CONCLUSION The NL11SN nebulizer ensured preferential nasal cavity aerosol deposition and successfully targeted the maxillary sinuses.


International Journal of Pharmaceutics | 2011

Impact of acoustic airflow nebulization on intrasinus drug deposition of a human plastinated nasal cast: New insights into the mechanisms involved

Marc Durand; Jérémie Pourchez; Gérald Aubert; Sandrine Le Guellec; Laurent Navarro; Valérie Forest; Philippe Rusch; Michèle Cottier

PURPOSE The impact of 100 Hz (Hertz) acoustic frequency airflow on sinus drug deposition of aerosols was investigated using a human plastinated nasal cast. The influence of drug concentration and endonasal anatomical features on the sinus deposition enhanced by the 100 Hz acoustic airflow was also examined. METHODS Plastinated models were anatomically, geometrically and aerodynamically validated (endoscopy, CT scans, acoustic rhinometry and rhinomanometry). Using the gentamicin as a marker, 286 experiments of aerosol deposition were performed. Changes of airborne particles metrology produced under different nebulization conditions (100 Hz acoustic airflow and gentamicin concentration) were also examined. RESULTS Aerodynamic and geometric investigations highlighted a global behaviour of plastinated models in perfect accordance with a nasal decongested healthy subject. The results of intrasinus drug deposition clearly demonstrated that the aerosols can penetrate into the maxillary sinuses. The 100 Hz acoustic airflow led to increase the deposition of drug into the maxillary sinuses by a factor 2-3 depending on the nebulization conditions. A differential intrasinus deposition of active substance depending on maxillary ostium anatomical features and drug concentration was emphasized. CONCLUSION The existence of a specific transport mechanism of penetration of nebulized particles delivered with acoustic airflow was proposed.


Journal of Aerosol Medicine and Pulmonary Drug Delivery | 2010

Evaluation of lung tolerance of ethanol, propylene glycol, and sorbitan monooleate as solvents in medical aerosols.

Jérôme Montharu; Sandrine Le Guellec; Birgit Kittel; Yvon Rabemampianina; J. Guillemain; Francis Gauthier; P. Diot; Michèle de Monte

BACKGROUND Aerosol therapy is an expanding technique allowing administration of drugs acting locally in the bronchial tree and lungs or acting systemically after absorption through the respiratory tract. However, the choice of solvents and adjuvants is a critical step in the formulation process of new drugs. Pulmonary tolerance of ethanol, propylene glycol and sorbitan ester was evaluated in a rat model of intratracheal administration using a Microsprayer in a 4-day toxicity study. METHODS Four groups of Sprague-Dawley rats (11 rats per group, n = 44) have received, on 4 consecutive days 150 microL of solutions containing the solvents, by intratracheal route using a IA-1B-2 inches-Microsprayer (PennCentury, Philadelphia, PA). Once a day, the rats received deionized water (control) or ethanol 10% or propylene glycol 30% or sorbitan monooleate 10%. All rats were sacrificed 24 h after the fourth administration. Biochemical analysis on bronchoalveolar lavage (BAL) fluid was performed on seven rats per group. The respiratory tract of the remaining four rats/group was examined histologically. RESULTS Biochemistry and histopathology findings demonstrated that under the conditions tested, deionized water, 10% ethanol, and 30% propylene glycol were tolerated in a qualitatively similar way presenting limited cellular reaction. In contrast, 10% sorbitan monooleate produced an accumulation of foamy macrophages in the lungs and a higher degree of inflammation. In addition, animals in this group showed higher polymorphonuclear neutrophil recruitment and total proteins levels in BAL fluid. CONCLUSION The overall results recommended ranking the vehicles according to the degree of inflammation which was induced: deionized water <10% ethanol < or =30% propylene glycol <10% Tween 80.


Laryngoscope | 2015

Effect of three‐drug delivery modalities on olfactory function in chronic sinusitis

Gregory Reychler; Coralie Colbrant; Caroline Huart; Sandrine Le Guellec; Laurent Vecellio; Giuseppe Liistro; Philippe Rombaux

Olfactory dysfunction is deemed to be a significant contributor to poor quality of life in chronic rhinosinusitis (CRS).


International Journal of Pharmaceutics | 2014

Assessing sinus aerosol deposition: Benefits of SPECT–CT imaging

Lara Leclerc; Jérémie Pourchez; Nathalie Prévôt; Laurent Vecellio; Sandrine Le Guellec; Michèle Cottier; Marc Durand

PURPOSE Aerosol inhalation therapy is one of the methods to treat rhinosinusitis. However the topical drug delivery to the posterior nose and paranasal sinuses shows only limited efficiency. A precise sinusal targeting remains a main challenge for aerosol treatment of sinus disorders. This paper proposes a comparative study of the nasal deposition patterns of micron and submicron particles using planar gamma-scintigraphy imaging vs. a new 3-dimensional (3D) imaging approach based on SPECT-CT measurements. METHODS Radiolabelled nebulizations have been performed on a plastinated model of human nasal cast coupled with a respiratory pump. First, the benefits provided by SPECT-CT imaging were compared with 2D gamma-scintigraphy and radioactive quantification of maxillary sinus lavage as reference for the sonic 2.8 μm aerosol sinusal deposition. Then, the impact on nasal deposition of various airborne particle sizes was assessed. RESULTS The 2D methodology overestimates aerosol deposition in the maxillary sinuses by a factor 9 whereas the 3D methodology is in agreement with the maxillary sinus lavage reference methodology. Then with the SPECT-CT approach we highlighted that the higher particle size was mainly deposited in the central nasal cavity contrary to the submicron aerosol particles (33.8 ± 0.6% of total deposition for the 2.8 μm particles vs. 1 ± 0.3% for the 230 nm particles). CONCLUSION Benefits of SPECT/CT for the assessment of radiolabelled aerosol deposition in rhinology are clearly demonstrated. This 3D methodology should be preferentially used for scintigraphic imaging of sinusal deposition in Human.


Pediatric Research | 2007

Lung Deposition of HFA Beclomethasone Dipropionate in an Animal Model of Bronchopulmonary Dysplasia

Jean-Christophe Dubus; Jérôme Montharu; Laurent Vecellio; Michèle de Monte; Anne de Muret; Arnaud Goucher; Sylvain Cantagrel; Alain Le Pape; Karen Mezzi; Caroline Majoral; Sandrine Le Guellec; P. Diot

The best delivery of a drug in ventilated neonates is obtained when using a small particle diameter solution administered via a spacer. Lung deposition of hydrofluoroalkane beclomethasone dipropionate (QVAR, 1.3 μm particles), delivered via an Aerochamber-MV15, was measured in piglets under conditions mimicking ventilated severely ill neonates (uncuffed 2.5 mm endotracheal tube; peak pressure 16 cm H2O; respiratory rate 40/min). After determining the mass and particle size distribution of the 99mTc-labeled and unlabeled drug, three lung deposition studies were performed: after 1 h of ventilation (controls, n = 18), after 48 h aggressive ventilation inducing an acute lung injury (nine piglets out of the controls), and after increasing the pressure to 24 cm H2O during drug delivery (five piglets out of the nine with acute lung injury). All piglets were then killed for lung histology. Results (median, range), expressed as a percentage of the delivered dose, were compared using an inferential or the Friedman test. While lung deposition was low, it was greater (p = 0.003) in controls (2.66%, 0.50–7.70) than in piglets with histologically confirmed acute lung injury (0.26%, 0.06–1.28) or under a high-pressure ventilation (1.01%, 0.30–2.15). Lung deposition of QVAR in an animal model of ventilated neonates is low, variable, and dramatically affected by lung injury.


Pharmaceutical Research | 2014

Validation of Anatomical Models to Study Aerosol Deposition in Human Nasal Cavities

Sandrine Le Guellec; Déborah Le Pennec; Stephane Gatier; Lara Leclerc; Maria Cabrera; Jérémie Pourchez; P. Diot; Gregory Reychler; Laurent Pitance; Marc Durand; François Jamar; Laurent Vecellio


European Respiratory Journal | 2014

Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis

Gregory Reychler; Coralie Colbrant; Caroline Huart; Sandrine Le Guellec; Laurent Vecellio; Giuseppe Liistro; Philippe Rombaux

Collaboration


Dive into the Sandrine Le Guellec's collaboration.

Top Co-Authors

Avatar

Laurent Vecellio

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

P. Diot

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marc Durand

Jean Monnet University

View shared research outputs
Top Co-Authors

Avatar

Gregory Reychler

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Jérôme Montharu

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

François Jamar

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Laurent Pitance

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Déborah Le Pennec

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge